Biosensors & POCT– category –
-
MDPI Review Maps Biosensors’ Evolution to Integrated Systems for Molecular Diagnostics and Longitudinal Clinical Monitoring
MDPI (Biosensors Journal) International Overview A new review from MDPI details the transformation of biosensors from simple analytical detectors into integrated systems crucial for molecular diagnostics, longitudinal monitoring, dynamic... -
Biosensors & POCT Weekly Report August 30, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report August 30, 2026 (PDF) — Download Weekly Report August 30, 2026 (PDF) — DownloadDownload 🎙 Podcast August 30, ... -
Latest Innovations in Point-of-Care Microdevices to be Unveiled at Microfluidics 2026 Conference in Berlin
Microfluidics 2026 Conference Germany Overview The 'Microfluidics 2026' conference in Berlin, held from August 27-28, will feature a session on point-of-care microdevices. This session will showcase the latest innovations in compact micr... -
TechRadar Hails ‘Diabetes Breakthrough’: FDA Approves Abbott’s World’s First Dual-Sensor CGM
TechRadar UK Overview TechRadar reported the FDA's approval of Abbott's Libre Duo 10 Day as a 'diabetes breakthrough.' This is the world's first dual-sensor Continuous Glucose Monitoring (CGM) system capable of simultaneously tracking bo... -
Epocrates Explains: Ketone Tracking Integrated into CGM with First-of-its-Kind Wearable, Enhancing Diabetic Ketoacidosis Prevention
Epocrates USA Overview Epocrates reports that Abbott's Libre Duo 10 Day system is the first wearable device to integrate ketone tracking with continuous glucose monitoring (CGM). This system provides real-time ketone trend data alongside... -
FDA Authorizes First Continuous Glucose-Ketone Monitoring Wearable for Diabetes Patients Aged 2 and Older: Libre Duo 10 Day
Patient Care Online USA Overview The FDA has authorized Abbott's Libre Duo 10 Day as the first continuous glucose-ketone monitoring system for diabetes patients aged 2 and older. This landmark approval significantly enhances patient safe... -
Abbott Wins FDA Nod for World’s First Dual Glucose-Ketone Sensor, Bolstering Diabetic Ketoacidosis Prevention
MDO Online USA Overview Abbott's Libre Duo 10 Day has received FDA authorization as the world's first Continuous Glucose Monitoring (CGM) system capable of continuously tracking both glucose and ketone levels. Developed to prevent diabet... -
FDA Approves World’s First Dual Glucose-Ketone Continuous Monitoring Wearable for Diabetes Patients: Early DKA Risk Detection Enabled
GIGAZINE Japan Overview GIGAZINE reports that the U.S. FDA has approved the world's first wearable device for continuous dual glucose and ketone monitoring in diabetes patients. This is Abbott's Libre Duo 10 Day, providing real-time data... -
FDA Clears First Continuous Glucose-Ketone Monitor: Abbott’s Libre Duo 10 Day Transforms Diabetes Care
Pharmacy Times USA Overview The FDA has authorized Abbott's Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for individuals aged 2 and older with diabetes. This marks the first continuous ketone monitoring wearable in t... -
HME News Reports: Abbott Gains FDA Clearance for Dual Sensing Technology, Marking New Step in DKA Prevention
HME News USA Overview HME News reports Abbott has received FDA authorization for its Libre Duo 10 Day system, which continuously monitors both glucose and ketones. This biowearable is designed to alert patients to rising ketone levels, c...
